The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) recommended approval for Roche’s Susvimo. The therapy treats neovascular (wet) age-related macular degeneration (nAMD), a leading cause of blindness in individuals over 60.
Susvimo utilizes a first-of-its-kind permanent and refillable eye implant for continuous drug delivery. This system requires as few as two treatments per year. Standard care currently involves frequent eye injections every one to two months.
Clinical studies demonstrated that Susvimo maintains patient vision at levels equivalent to monthly injections. The European Commission expects to issue a final decision in the near future.